Cristhian Emmanuel Scatularo *

Autor invitado por SIIC

Diagnóstico diferencial y tratamiento

ABORDAJE DEL TROMBOEMBOLISMO PULMONAR AGUDO EN TIEMPOS DE SARS-COV-2

La infección por SARS-CoV-2 aumenta el riesgo de presentar tromboembolismo pulmonar agudo debido a la activación de la cascada de coagulación, lo que sugiere un posible beneficio clínico de la anticoagulación en estos pacientes. Asimismo, existen similitudes clínicas entre ambas afecciones, y no son mutuamente excluyentes, por lo que establecer un adecuado diagnóstico diferencial es fundamental.

*Cristhian Emmanuel Scatularo
describe para SIIC los aspectos relevantes de su trabajo
TROMBOEMBOLISMO PULMONAR AGUDO EN TIEMPOS DE SARS-COV-2: DIAGNÓSTICO Y TRATAMIENTO
Institución principal de la investigación
*Sanatorio de la Trinidad - Palermo, Ciudad de Buenos Aires, Argentina
Imprimir nota

Comprar este artículo
Otros artículos escogidos

Referencias bibliográficas
1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708-1720, 2020.
2. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 323(13):1239-1242, 2020.
3. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 368:m1091, 2020.
4. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844-847, 2020.
5. Wong RS, Wu A, To KF, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BM 326(7403):1358-1362, 2003.
6. Klok F, Kruip M, Van der Meer N, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020 Apr 10. [Epub ahead of print]
7. Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation 142(2):184-186, 2020.
8. Ullah W, Saeed R, Sarwar U, et al. COVID-19 complicated by acute pulmonary embolism and right-sided heart failure. JACC Case Reports 2(9):1379-1382, 2020.
9. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19. Eur Heart J. 2020 Mar 30 [Epub ahead of print]
10. Milbrandt EB, Reade MC, Lee M, et al. Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med 15(11-12):438-445, 2009.
11. Carsana L, Sonzogni A, Nasr A, et al. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. Lancet Infect Dis 20(10):1135-1140, 2020.
12. Wichmann D, Sperhake J, Lïtgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020; [Epub ahead of print 6 May 2020]
13. Digby GC, Kukla P, Zhan ZQ, et al. The value of electrocardiographic abnormalities in the prognosis of pulmonary embolism: a consensus paper. Ann Noninvasive Electrocardiol 20(3):207-223, 2015.
14. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270-273, 2020.
15. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323(11):1061-1069, 2020.
16. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180(7):934-943, 2020.
17. Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Resp J 54(3):1901647, 2019.
18. B?lohlïvek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol 18(2):129-138, 2013.
19. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395:497-506, 2020.
20. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 8(5):475-481, 2020.
21. Gao Y, Li T, Han M, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 92(7):791-796, 2020.
22. Lippi G, Salvagno GL, Ippolito L, et al. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis 21:459-463, 2010.
23. Lippi G, Plebani M, Michael Henry B. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 506:145-148, 2020.
24. Lippi G, Favaloro EJ. D-dimer is associated with severity of coronavirus disease 2019 (COVID-19): a pooled analysis. Thromb Haemost 120(5):876-878, 2020.
25. Witkowski M, Landmesser U, Rauch U. Tissue factor as a link between inflammation and coagulation. Trends Cardiovasc Med 26(4):297-303, 2016.
26. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395(10229):1033-1034, 2020.
27. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol 5(5):428-430, 2020.
28. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 382(17):e38, 2020.
29. Léonard-Lorant I, Delabranche X, Séverac F, et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. Radiolog 296(3):E189-E191, 2020.
30. Kearon C, de Wit K, Parpia S, et al.; Investigators PES. Diagnosis of pulmonary embolism with D-dimer. N Engl J Med 381(22):2125-2134, 2019.
31. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395:1054-1062, 2020.
32. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 103:1718-1720, 2001.
33. Abul Y, Karakurt S, Ozben B, et al. C-reactive protein in acute pulmonary embolism. J Investig Med 59(1):8-14, 2011.
34. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 75(23):2950-2973, 2020.
35. Choi AD, Abbara S, Branch KR, et al. Society of Cardiovascular Computed Tomography Guidance for Use of Cardiac Computed Tomography Amidst the COVID-19 Pandemic. J Cardiovasc Comput Tomogr 2020 Mar 21 [Epub ahead of print]
36. Liu P, Tan X. Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology 8:200257, 2020.
37. Zuckier LS, Moadel R, Haramati L, Freeman L. Diagnostic Evaluation of Pulmonary Embolism During the COVID-19 Pandemic. J Nucl Med 61(5):630-631, 2020.
38. Jacobi A, Chung M, Bernheim, A, Eber C. Portable chest X-ray in coronavirus disease-19 (COVID-19): a pictorial review. Clinical Imaging 64:35-42, 2020.
39. Moore AJE, Wachsmann, J, Chamarthy, MR, et al. Imaging of acute pulmonary embolism: an update. Cardiovasc Diagn Ther 8(3):225-243, 2018.
40. Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis 63(3):390-391, 2020.
41. Januzzi JL. Troponin and BNP use in COVID-19. Cardiology Magazine: American College of Cardiology, 2020.
42. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction 2018. J Am Coll Cardiol 72:2231-2264, 2018.
43. Kirkpatrick JN, Grimm R, Johri AM, et al. Recommendations for echocardiography laboratories participating in cardiac Point of Care Cardiac Ultrasound (POCUS) and Critical Care Echocardiography Training: report from the American Society of Echocardiography. J Am Soc Echocardiogr 33(4):409-422, 2020.
44. Kumar P, Gordon LA, Brooks KM, et al. Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport and the pharmacokinetic/pharmacodynamic disposition of dabigatran. Antimicrob Agents Chemother 61(11):e01201-01217, 2017.
45. Stïllberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz 40(Suppl 2):140-145, 2015.
46. Egan G, Hughes CA, Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother 48(6):734-740, 2014.
47. Steffel J, Verhamme P, Potpara TS, et al.; ESC Scientific Document Group. The 2018 EHRA Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330-1393, 2018.
48. Lew TW, Kwek TK, Tai D, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA 290:374-380, 2003.
49. Kucher N, Goldhaber SZ. Managemenet of massive pulmonary embolism. Circulation 112(2):e28-32, 2005.
50. Ain DL, Albaghdadi M, Giri J, et al. Extra-corporeal membrane oxygenation and outcomes in massive pulmonary embolism: Two eras at an urban tertiary care hospital. Vasc Med 23:60-64, 2018.
51. De Winter MA, Vlachojannis GJ, Ruigrok D, et al. Rationale for catheter-based therapies in acute pulmonary embolism. Eur Heart J 21(I):I16-I22, 2019.
52. Giri J, Sista AK, Weinberg I, et al. Interventional therapies for acute pulmonary embolism: current status and principles for the development of novel evidence: a Scientific Statement from the AHA. Circulation 140:e774-e801, 2019.
53. Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a metaanalysis. JAMA 311:2414-2421, 2014.
54. Jimenez D, Bikdeli B, Marshall PS, Tapson V. Aggressive treatment of intermediate-risk patients with acute symptomatic pulmonary embolism. Clin Chest Med 39:569-581, 2018.
55. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the AHA. Circulation 123:1788-830, 2011.
56. Romaguera R, Cruz-Gonzalez I, Ojeda S, et al. Gestión de salas de procedimientos invasivos cardiológicos durante el brote de coronavirus COVID-19. Documento de consenso de la Asociación de Cardiología Intervencionista y la Asociación del Ritmo Cardíaco de la SEC. REC Interv Cardiol 2:106-111, 2020.
57. Welt Frederick GP, Shah PB, Aronow HD, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC Interventional Council and SCAI. J Am Coll Cardiol 75:2372-2375, 2020.
58. Wood DA, Sathananthan J, Gin K, et al. Precautions and procedures for coronary and structural cardiac interventions during the COVID-19 pandemic: Guidance from Canadian Association of Interventional Cardiology. Can J Cardiol 36(5):780-783, 2020.
59. Kolkailah AA, Hirji S Piazza, Ejiofor JI, et al. Surgical pulmonary embolectomy and catheter-directed thrombolysis for treatment of submassive pulmonary embolism. J Card Surg 33(5):252-259, 2018.
60. Bikdeli B, Chatterjee S, Desai NR, et al. Inferior vena cava filters to prevent pulmonary embolism: systematic review and meta-analysis. J Am Coll Cardiol 70:1587-1597, 2017.
61. Hollander JE, Carr BG. Virtually perfect?: Telemedicine for Covid-19. N Engl J Med 382:1679-1681, 2020.
62. Boukhris M, Hillani A, Moroni F, et al. Cardiovascular implications of the COVID-19 pandemic: a global perspective. Can J Cardiol 36(7):1068-1080, 2020.
63. Helmes J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 46(6):1089-1098, 2020.
64. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 191:9-14, 2020.
65. Ciceri F, Beretta L, Scandroglio AM, et al. Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis. Crit Care Resusc 22(2):95-97, 2020.
66. McGonagle D, O'Donnell J, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol 2(7):e437-e445, 2020.
67. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094-1099, 2020.
68. Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol 76(1):122-124, 2020.